Nurix Therapeutics, Inc. Common stock (NRIX) Stock Price
NRIXStock
$26.21+178.53%52W
Market Cap$2.72B
P/E—
PEG Ratio—
Div yield—
Beta1.80
NRIX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)51.68%
Price vs S&P 500 (4W)11.34%
VGM Score44.92
NRIX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.72 | -$0.81 | -13.07%(-$0.09) | |
| Q1 2026 | -$0.76 | -$0.79 | -3.33%(-$0.03) | |
| Q4 2025 | -$0.92 | -$0.82 | +10.85%(+$0.10) | |
| Q3 2025 | -$0.85 | -$1.03 | -21.07%(-$0.18) |
NRIX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.30
4.30
4.23
4.23
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NRIXNurix Therapeutics, Inc. Common stock | F | D | A | $26.21 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Nurix Therapeutics, Inc. Common stock
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies for cancer and inflammatory diseases using an AI-enhanced discovery platform. The company's pipeline includes candidates such as Bexobrutideg and Zelebrudomide that target specific disease-causing proteins in immune and oncology-related pathways.